These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1213656)

  • 1. On an attempt to treat primary and secondary osteoporosis with human growth hormone.
    Kruse HP; Kuhlencordt F
    Horm Metab Res; 1975 Nov; 7(6):488-91. PubMed ID: 1213656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.
    Marini JC; Hopkins E; Glorieux FH; Chrousos GP; Reynolds JC; Gundberg CM; Reing CM
    J Bone Miner Res; 2003 Feb; 18(2):237-43. PubMed ID: 12568401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of growth hormone in osteoporosis (author's transl)].
    Kuhlencordt F; Lozano-Tonkin C; Kruse HP; Schneider C; Sommer E
    Klin Wochenschr; 1974 Dec; 52(23):1130-1. PubMed ID: 4444231
    [No Abstract]   [Full Text] [Related]  

  • 5. [Correlation between hydroxyprolinuria, alkaline phosphatasemia and Ca45 dynamics].
    Gennari C; Rubegni M; Forconi S; Romano S
    Boll Soc Ital Biol Sper; 1965 May; 41(10):508-12. PubMed ID: 5875588
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
    Kuntz D; Marie P; Berhel M; Caulin F
    Int J Clin Pharmacol Res; 1986; 6(2):157-62. PubMed ID: 3522444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
    Kassem M; Brixen K; Blum WF; Mosekilde L; Eriksen EF
    J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis.
    Wright NM
    J Pediatr Endocrinol Metab; 2000 Sep; 13 Suppl 2():999-1002. PubMed ID: 11086654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of calcium supplements on plasma alkaline phosphatase and urinary hydroxyproline in postmenopausal women.
    Horowitz M; Need AG; Philcox JC; Nordin BE
    Horm Metab Res; 1985 Jun; 17(6):311-2. PubMed ID: 4018720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D metabolism in osteogenesis imperfecta during calcitonin therapy.
    Nishi Y; Hyodo S; Yoshimitsu K; Sawano K; Yamaoka K; Seino Y; Usui T
    Pediatrics; 1984 Apr; 73(4):538-42. PubMed ID: 6546792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sex hormones on bone in primary osteoporosis.
    Riggs BL; Jowsey J; Kelly PJ; Jones JD; Maher FT
    J Clin Invest; 1969 Jun; 48(6):1065-72. PubMed ID: 5771187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-term calcitonin therapy on the clinical course of osteogenesis imperfecta.
    Rosenberg E; Lang R; Boisseau V; Rojanasathit S; Avioli LV
    J Clin Endocrinol Metab; 1977 Feb; 44(2):346-55. PubMed ID: 557059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some effects of ethinyl oestradiol on calcium and phosphorus metabolism in osteoporosis.
    Young MM; Jasani C; Smith DA; Nordin BE
    Clin Sci; 1968 Jun; 34(3):411-7. PubMed ID: 5666871
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluoride therapy in metabolic bone disease.
    Spencer H; Kramer L; Wiatrowski E; Lender M
    Isr J Med Sci; 1984 May; 20(5):373-80. PubMed ID: 6469556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of porcine calcitonin in osteogenesis imperfecta tarda.
    Castells S; Inamdar S; Baker RK; Wallach S
    J Pediatr; 1972 May; 80(5):757-62. PubMed ID: 5062955
    [No Abstract]   [Full Text] [Related]  

  • 18. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
    Chapuy MC; Meunier P; Terrier M; David L; Vignon G
    Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogenic antagonism of metabolic effects of administered growth hormone.
    Schwartz E; Wiedemann E; Simon S; Schiffer M
    J Clin Endocrinol Metab; 1969 Sep; 29(9):1176-81. PubMed ID: 4309155
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)].
    Alexandre C; Chapuy MC; Bressot C; Vignon E; Arlot M; Mathieu L; Edouard C; Johnston CC; Meunier PJ
    Nouv Presse Med; 1980 Nov; 9(45):3429-33. PubMed ID: 6777752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.